Sanjivani Paranteral Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/dpf1epif8d50t3p8c5uo16b2.pdf

Key Takeaways


Pune Plant & Capacity Expansion

Ashwani Khemka: "Now there's an online system. In the online system, there are a lot of companies that are in the pipeline. We are, in fact, ahead. There are many companies in India who have been in line for the last 8 to 9 months. And once those are processed, they can't do. For us, it has been done out of the way to take it ahead on the CDSCO website, Delhi."

Revenue & Product Mix

Srivardhan Khemka: "Sir, no particular reason. As you know, the total size of the company's revenue is not that large. It is just order lumpiness. This quarter, it has dropped. The next quarter, it will pick up. It's nothing to do specifically with the business, per se."

Margins & Cost Structure

Srivardhan Khemka: "What happens is when we add new products, the economies of scale are not there. Once the product is mature, like 3-4 years, then the economies of scale kick in and then our EBITDA margins are bound to improve. So what we see is the first batch of products will turn mature in, say, FY '27. So, we see the EBITDA margins to improve in that year."

Geographic & Segment Outlook

Srivardhan Khemka: "We are planning to even hire agents and teams out there. So, the scale-up on that front will be slow, but the margins will be better."

Guidance & Commitments

CommitmentSpecificsTimeline
Pune plant commercial productionCommercial license expected, production to startEnd of August or first week of September 2025
SPL Infusion plant ramp-upReach 65-70% capacity, INR75-80 cr top lineFirst year of operation
Full-year FY26 revenueAround INR75-80 croresFY26
Full-year FY26 EBITDA marginAround 15% at EBITDA level for base businessFY26
EBITDA margin improvementEconomies of scale kick in as first batch of products matureFY27
CDMO growthMinimum 20% growth over prior year, order book already in handFY26
Nutraceutical revenueRecovery and growth from current levelsFrom here on
Supply chain bottlenecksTemporary bottlenecks expected to normalize progressivelyOver the year
Prague JV income recognitionIncome shown in balance sheetQ4 FY26

Key Metrics

MetricQ1 FY26
Revenue₹17.9 cr, +8.9% YoY
EBITDA₹2.7 cr, +10.8% YoY
EBITDA margin15.0%, vs 14.7% in Q1 FY25
Profit after tax₹1.7 cr, flat YoY due to higher depreciation and interest expense
Revenue guidance FY26₹75-80 cr, confirmed by management
EBITDA margin guidance FY26~15% for base business
Export-domestic mix73.7% export, 26.3% domestic
Product mix: injectables, tablets, nutraceuticals50.2%, 49.3%, 0.4% respectively
Injectable revenue (sequential)₹9 cr, down from ₹13 cr in Q4 FY25 (per an analyst's math)
New products added8 in Q1 and Q2 combined
CDMO business growth target FY26~20% minimum
SPL Infusion plant capacity ramp-up65-70% expected in first year
SPL Infusion plant revenue potential₹75-80 cr top line
Debt₹6 cr, down from ~₹8 cr in Q4 FY25
Trade receivables~₹8 cr